GYRE
NASDAQ HealthcareGyre Therapeutics, Inc. - Common Stock
Biotechnology
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
๐ Market Data
| Price | $7.55 |
|---|---|
| Volume | 1,203,599 |
| Market Cap | 800.55M |
| Beta | 4.830 |
| RSI (14-Day) | 64.7 |
| 200-Day MA | $7.11 |
| 50-Day MA | $6.48 |
| 52-Week High | $9.42 |
| 52-Week Low | $5.44 |
| Forward P/E | 125.83 |
| Price / Book | 7.42 |
๐ฏ Investment Strategy Scores
GYRE scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (99/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ช Falling Knife (16/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find GYRE in your text
Paste any article, transcript, or post โ the tool will extract GYRE and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-18.